Edward F. McClay

2.0k total citations
57 papers, 1.3k citations indexed

About

Edward F. McClay is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Edward F. McClay has authored 57 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 18 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Edward F. McClay's work include Immunotherapy and Immune Responses (11 papers), CAR-T cell therapy research (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Edward F. McClay is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), CAR-T cell therapy research (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Edward F. McClay collaborates with scholars based in United States, Germany and France. Edward F. McClay's co-authors include Steven C. Plaxe, Stephen B. Howell, Carol DePriest, Robert O. Dillman, Patricia S. Braly, Robert E. Bellet, Andrew N. Cornforth, Michael J. Mastrangelo, David Berd and R D Christen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Edward F. McClay

57 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edward F. McClay United States 21 757 403 359 229 179 57 1.3k
Ewan Brown United Kingdom 18 501 0.7× 510 1.3× 271 0.8× 132 0.6× 104 0.6× 30 1.2k
Dana M. Roque United States 20 480 0.6× 348 0.9× 165 0.5× 156 0.7× 266 1.5× 61 1.1k
Darren Ennis United Kingdom 18 566 0.7× 401 1.0× 260 0.7× 144 0.6× 332 1.9× 26 1.3k
C. Sturgeon United Kingdom 13 916 1.2× 473 1.2× 181 0.5× 341 1.5× 87 0.5× 28 1.6k
H. Hollema Netherlands 19 763 1.0× 431 1.1× 186 0.5× 202 0.9× 268 1.5× 38 1.5k
Laure Favier France 16 573 0.8× 328 0.8× 193 0.5× 197 0.9× 119 0.7× 61 1.0k
Gudrun Pohl Austria 19 579 0.8× 661 1.6× 122 0.3× 150 0.7× 147 0.8× 35 1.4k
Salvatore Lopez Italy 25 551 0.7× 369 0.9× 195 0.5× 213 0.9× 619 3.5× 89 1.6k
Sabrina Chiara Cecere Italy 20 615 0.8× 428 1.1× 178 0.5× 200 0.9× 525 2.9× 71 1.4k

Countries citing papers authored by Edward F. McClay

Since Specialization
Citations

This map shows the geographic impact of Edward F. McClay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward F. McClay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward F. McClay more than expected).

Fields of papers citing papers by Edward F. McClay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward F. McClay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward F. McClay. The network helps show where Edward F. McClay may publish in the future.

Co-authorship network of co-authors of Edward F. McClay

This figure shows the co-authorship network connecting the top 25 collaborators of Edward F. McClay. A scholar is included among the top collaborators of Edward F. McClay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward F. McClay. Edward F. McClay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strauss, Julius, Margaret E. Gatti‐Mays, Byoung Chul Cho, et al.. (2021). 957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1. Annals of Oncology. 32. S829–S829. 5 indexed citations
2.
Cho, Byoung Chul, Amaury Daste, Alain Ravaud, et al.. (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. Journal for ImmunoTherapy of Cancer. 8(2). e000664–e000664. 69 indexed citations
3.
Verschraegen, Claire F., Guy Jérusalem, Edward F. McClay, et al.. (2020). Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. Journal for ImmunoTherapy of Cancer. 8(2). e001064–e001064. 19 indexed citations
4.
Jérusalem, Guy, Franklin Chen, David R. Spigel, et al.. (2017). OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 12(1). S252–S252. 19 indexed citations
5.
Dillman, Robert O., Edward F. McClay, Neil M. Barth, et al.. (2015). Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Cancer Biotherapy and Radiopharmaceuticals. 30(5). 187–194. 18 indexed citations
6.
Dillman, Robert O., Andrew N. Cornforth, Carol DePriest, et al.. (2012). Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy. Journal of Immunotherapy. 35(8). 641–649. 60 indexed citations
7.
Dillman, Robert O., Senthamil R. Selvan, Patric M. Schiltz, et al.. (2009). Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report. Cancer Biotherapy and Radiopharmaceuticals. 24(3). 311–319. 56 indexed citations
8.
Berger, Adam C., et al.. (2009). Completely Regressed Cutaneous Melanocytic Lesion: Was It Benign or Was It Malignant?. Seminars in Oncology. 36(5). 375–379. 2 indexed citations
9.
Bogart, Jeffrey A., Dorothy Watson, Edward F. McClay, et al.. (2008). Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235. Lung Cancer. 62(1). 92–98. 6 indexed citations
10.
11.
Dillman, Robert O., Senthamil R. Selvan, Patric M. Schiltz, et al.. (2004). Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis. Cancer Biotherapy and Radiopharmaceuticals. 19(5). 658–665. 34 indexed citations
12.
Dillman, Robert O., Senthamil R. Selvan, Patric M. Schiltz, et al.. (2004). Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis. Cancer Biotherapy and Radiopharmaceuticals. 19(5). 658–665. 16 indexed citations
13.
Jones, Vicky, et al.. (2003). Metastatic Melanoma in a Patient with Clouston Syndrome Successfully Treated with Isolated Hyperthermic Limb Perfusion. Journal of Cutaneous Medicine and Surgery. 7(1). 43–46. 4 indexed citations
14.
Aebi, Stefan, Thomas W. Schnider, Gerrit Los, et al.. (1999). A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemotherapy and Pharmacology. 44(3). 259–265. 16 indexed citations
15.
McClay, Edward F., et al.. (1994). Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?. Journal of Clinical Oncology. 12(3). 617–626. 39 indexed citations
16.
Plaxe, Steven C., James L. Freddo, Sinil Kim, et al.. (1994). Phase I Trial of Cisplatin in Combination with Glutathione. Gynecologic Oncology. 55(1). 82–86. 18 indexed citations
17.
Braly, Patricia S., et al.. (1994). A Comparison of Intravenous versus Intraperitoneal Chemotherapy for the Initial Treatment of Ovarian Cancer. Gynecologic Oncology. 54(3). 338–344. 74 indexed citations
18.
19.
McClay, Edward F., Steven C. Plaxe, S. S. C. YEN, et al.. (1993). Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin.. Journal of Clinical Oncology. 11(12). 2417–2426. 31 indexed citations
20.
Kim, S., Stephen B. Howell, Edward F. McClay, et al.. (1993). Dose intensification of cisplatin chemotherapy through biweekly administration. Annals of Oncology. 4(3). 221–227. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ewan Brown Breakdown of academic impact, for papers by Dana M. Roque Breakdown of academic impact, for papers by Darren Ennis Breakdown of academic impact, for papers by C. Sturgeon Breakdown of academic impact, for papers by H. Hollema Breakdown of academic impact, for papers by Laure Favier Breakdown of academic impact, for papers by Gudrun Pohl Breakdown of academic impact, for papers by Salvatore Lopez Breakdown of academic impact, for papers by Sabrina Chiara Cecere
Rankless by CCL
2026